Bafna Pharmaceuticals (BOM:532989) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:532989 Bafna Pharmaceuticals Ltd BOM:532989
58 GF Score
Price ₹229.05
GF Value ₹94.13
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Bafna Pharmaceuticals Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Bafna Pharmaceuticals Valuation Rank Related Terms

BOM:532989
58GF Score
Bafna Pharmaceuticals Ltd BOM:532989
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bafna Pharmaceuticals (BOM:532989) Overvalued in 2026?

Based on GuruFocus' analysis, Bafna Pharmaceuticals stock appears to be overvalued. The current stock price of ₹229.05 is trading 143.3% above its estimated GF Value™ of ₹94.13. GuruFocus considers Bafna Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for BOM:532989:

  • Valuation Rank:
  • GF Value™: ₹94.13 vs. price of ₹229.05 (143.3% above fair value)
  • GF Score™: 58/100 with 9 warning signs

No single metric tells the full story. See the BOM:532989 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bafna Pharmaceuticals Business Description

Other Exchanges BAFNAPH:India
Address Thambu Chetty Street, New No. 68, Old No. 299, Bafna Towers, Chennai, TN, IND, 600001
Bafna Pharmaceuticals Ltd is an Indian pharmaceutical company mainly offering Contract Research and Manufacturing (CRAMS), Technology Transfers, Formulation, and Analytical Development services. It is engaged in the business of manufacturing finished pharmaceutical formulations, specializing in non-betalactam solid oral dosage forms, besides other emerging and potential products and forms in various therapeutic areas such as cardiology, lifestyle and potent drugs, and pain management. The company delivers generic pharmaceutical products for the UK, Australia, the EU, and emerging markets. In addition, it has launched its own brands in Sri Lanka, the Philippines, Tanzania, and Nigeria, offering products for some high-demand therapies like diabetes, cardiovascular, and oncology.
58GF Score

Get the complete analysis for BOM:532989

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹229.05
Price
₹94.13
GF Value